Cargando…
T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
Adoptive cell transfer (ACT) using chimeric antigen receptor (CAR)‐modified T cells can induce durable remissions in patients with refractory B‐lymphoid cancers. By contrast, results applying CAR‐modified T cells to solid malignancies have been comparatively modest. Alternative strategies to redirec...
Autores principales: | Chandran, Smita S., Klebanoff, Christopher A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027847/ https://www.ncbi.nlm.nih.gov/pubmed/31355495 http://dx.doi.org/10.1111/imr.12772 |
Ejemplares similares
-
Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors
por: Kim, Nayoung, et al.
Publicado: (2021) -
Immune metabolism in PD-1 blockade-based cancer immunotherapy
por: Kumar, Alok, et al.
Publicado: (2020) -
Engineered biomaterials for cancer immunotherapy
por: Cai, Lulu, et al.
Publicado: (2020) -
Current and emerging trends in prostate cancer immunotherapy
por: Schatz, Adam, et al.
Publicado: (2019) -
Perspectives on the clinical development of immunotherapy in prostate cancer
por: Cordes, Lisa M, et al.
Publicado: (2018)